2-甲基-6-(三氟甲基)烟酸甲酯 | 205582-88-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-6-(三氟甲基)烟酸甲酯
• 中文别名: 2-甲基-6-三氟甲基吡啶-3-羧酸甲酯
• 英文名称: methyl 2-methyl-6-(trifluoromethyl)nicotinate
• 英文别名: 2-methyl-6-trifluoromethyl-nicotinic acid methyl ester；methyl 2-methyl-6-(trifluoromethyl)pyridine-3-carboxylate
• CAS: 205582-88-3
• 化学式: C₉H₈F₃NO₂
• mdl: MFCD01311989
• 分子量: 219.163
• InChiKey: NEBSPXCPFDLIHP-UHFFFAOYSA-N

物化性质

• 沸点：
  209.0±40.0 °C(Predicted)
• 密度：
  1.286±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-甲基-6-(三氟甲基)烟酸甲酯 在 potassium phosphate 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 氯化亚砜 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 三溴化硼 、 sodium carbonate 、 potassium carbonate 、 caesium carbonate 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 32.67h， 生成 8-(4-chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)-pyridin-3-yl)methyl)-7-(2-methylpyrimidin-5-yl)-[1,2,4]triazolo[4,3-b]pyridazine-3,6(2H,5H)-dione
  参考文献：
  名称：

  Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties

  摘要：

  Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical compounds. An in vitro and in vivo clearance data set revealed a lack of correlation; however, when compounds with <5% free fraction were excluded, a more predictable correlation was observed. Compounds with log P between 3 and 4 were likely to have significant free fraction, so we designed compounds in this range to give more predictable clearance values. This strategy produced compounds with desirable in vivo half-lives, ultimately leading to the discovery of compound 46. The progression of compound 46 was halted due to the contemporaneous marketing and clinical withdrawal of other centrally acting CB1 antagonists; however, the design strategy successfully delivered a potent CB1 antagonist with the desired pharmacokinetic properties and a clean off-target profile.

  DOI：

  10.1021/jm4010835
• 作为产物：
  描述：

  methyl 6-methyl-4-oxo-2-(trifluoromethyl)-2,3-dihydro-1H-pyridine-5-carboxylate 在 吡啶 、 溴 、 palladium diacetate 、 三苯基膦 作用下， 以 乙腈 为溶剂， 反应 18.0h， 生成 2-甲基-6-(三氟甲基)烟酸甲酯
  参考文献：
  名称：

  Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from 4,4,4-trifluoro-3-aminobutanoates

  摘要：

  该发明公开了一种从4,4,4-三氟-3-氨基丁酸酯出发，经烯胺和二氢吡啶酮制备取代的6-三氟甲基吡啶-3-羧酸衍生物的方法。

  公开号：

  EP2821398A1

文献信息

• Triazolopyrimidine cannabinoid receptor 1 antagonists
  申请人：Wu Gang

  公开号：US20060287341A1

  公开（公告）日：2006-12-21

  The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R 1 , R 2 , R 3 , R 4 and R 5 are described herein.

  本申请描述了根据公式I和II的化合物，包括至少一种符合公式I或II的化合物的药物组合物，以及可选地包括一种或多种额外治疗剂的药物组合物，并且使用根据公式I和II的化合物进行治疗的方法，无论是单独使用还是与一种或多种额外治疗剂结合使用。这些化合物具有以下一般公式：包括所有的前药、溶剂化合物、药用可接受盐和立体异构体，其中R1、R2、R3、R4和R5如本文所述。
• Triazolopyridine cannabinoid receptor 1 antagonists
  申请人：Sun Chongqing

  公开号：US20070004772A1

  公开（公告）日：2007-01-04

  The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R 1 , R 2 , R 3 , R 4 and R 5 are described herein.

  本申请描述了符合I式的化合物，包括至少一种符合I式的化合物和可选地一种或多种额外的治疗剂的药物组合物，以及使用符合I式的化合物进行治疗的方法，无论是单独使用还是与一种或多种额外的治疗剂结合使用。这些化合物具有以下一般式： 包括所有的前药、溶剂化合物、药用盐和立体异构体，其中R1、R2、R3、R4和R5如本文所述。
• Herbicidal composition
  申请人：——

  公开号：US20040106519A1

  公开（公告）日：2004-06-03

  A herbicidal composition that, in addition to comprising customary inert formulation adjuvants, comprises a) a compound of formula I 1 wherein the substituents are as defined in claim 1, and b) a synergistically effective amount of one or more compounds of formulae 2.1 to 2.51. The compositions according to the invention may also comprise a safener.

  一种除草剂组合物，除了包括惯常的惰性配方助剂外，还包括 a) 公式I的化合物 其中取代基如权利要求1中定义的那样，以及b) 一种或多种公式2.1至2.51的化合物的协同有效量。根据本发明的组合物还可以包括一种安全剂。
• Substituted pyridine herbicides
  申请人：——

  公开号：US20030040437A1

  公开（公告）日：2003-02-27

  1 Compounds of formula (I), in which the substituents are as defined in claim 1 and the agrochemically tolerated salts M+ and all stereoisomers and tautomers of the compounds of formula (I) are suitable for use as herbicides.

  式（I）化合物，其中取代基如权利要求1中定义的那样，以及农药中可容忍的盐M+和式（I）化合物的所有立体异构体和互变异构体均适用于用作除草剂。
• Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：EP1882687A1

  公开（公告）日：2008-01-30

  This present invention relates to novel compounds, of the formula (I), isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1;VR1;TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis and pancreatitis.

  这项发明涉及新化合物，其化学式为(I)，其异构体或其药学上可接受的盐作为辣椒素受体（辣椒素受体1; VR1; TRPV1）拮抗剂；以及含有该化合物的药物组合物。本发明提供了一种用于预防或治疗疾病的药物组合物，如疼痛、关节炎炎症性疾病、神经病、艾滋病相关神经病、神经损伤、神经退行性疾病、中风、包括尿失禁、膀胱过敏、膀胱炎、胃十二指肠溃疡、肠易激综合征（IBS）和炎症性肠病（IBD）、粪便紧急情况、胃食管反流病（GERD）、克罗恩病、哮喘、慢性阻塞性肺病、咳嗽、神经症/过敏/炎症性皮肤病、牛皮癣、瘙痒症、疹痒症、皮肤、眼睛或粘膜刺激、听觉过敏、耳鸣、前庭过敏、阵发性眩晕、心脏疾病如心肌缺血、与头发生长有关的疾病如脱发、脱发、鼻炎和胰腺炎。